» Articles » PMID: 37742032

Multi-omics Analysis Reveals Attenuation of Cellular Stress by Empagliflozin in High Glucose-treated Human Cardiomyocytes

Abstract

Background: Sodium-glucose cotransporter 2 (SGLT2) inhibitors constitute the gold standard treatment for type 2 diabetes mellitus (T2DM). Among them, empagliflozin (EMPA) has shown beneficial effects against heart failure. Because cardiovascular diseases (mainly diabetic cardiomyopathy) are the leading cause of death in diabetic patients, the use of EMPA could be, simultaneously, cardioprotective and antidiabetic, reducing the risk of death from cardiovascular causes and decreasing the risk of hospitalization for heart failure in T2DM patients. Interestingly, recent studies have shown that EMPA has positive benefits for people with and without diabetes. This finding broadens the scope of EMPA function beyond glucose regulation alone to include a more intricate metabolic process that is, in part, still unknown. Similarly, this significantly increases the number of people with heart diseases who may be eligible for EMPA treatment.

Methods: This study aimed to clarify the metabolic effect of EMPA on the human myocardial cell model by using orthogonal metabolomics, lipidomics, and proteomics approaches. The untargeted and multivariate analysis mimicked the fasting blood sugar level of T2DM patients (hyperglycemia: HG) and in the average blood sugar range (normal glucose: NG), with and without the addition of EMPA.

Results: Results highlighted that EMPA was able to modulate and partially restore the levels of multiple metabolites associated with cellular stress, which were dysregulated in the HG conditions, such as nicotinamide mononucleotide, glucose-6-phosphate, lactic acid, FA 22:6 as well as nucleotide sugars and purine/pyrimidines. Additionally, EMPA regulated the levels of several lipid sub-classes, in particular dihydroceramide and triacylglycerols, which tend to accumulate in HG conditions resulting in lipotoxicity. Finally, EMPA counteracted the dysregulation of endoplasmic reticulum-derived proteins involved in cellular stress management.

Conclusions: These results could suggest an effect of EMPA on different metabolic routes, tending to rescue cardiomyocyte metabolic status towards a healthy phenotype.

Citing Articles

Critical Appraisal of Pharmaceutical Therapy in Diabetic Cardiomyopathy-Challenges and Prospectives.

Khattab E, Kyriakou M, Leonidou E, Sokratous S, Mouzarou A, Myrianthefs M Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861195 PMC: 11768626. DOI: 10.3390/ph18010134.


Empagliflozin protects against heart failure with preserved ejection fraction partly by inhibiting the senescence-associated STAT1-STING axis.

Shi Y, Zhao L, Wang J, Liu X, Bai Y, Cong H Cardiovasc Diabetol. 2024; 23(1):269.

PMID: 39044275 PMC: 11267814. DOI: 10.1186/s12933-024-02366-0.


Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy.

Nakamura M J Pharm Pharm Sci. 2024; 27:12568.

PMID: 38706718 PMC: 11066298. DOI: 10.3389/jpps.2024.12568.


The redox-active defensive Selenoprotein T as a novel stress sensor protein playing a key role in the pathophysiology of heart failure.

De Bartolo A, Pasqua T, Romeo N, Rago V, Perrotta I, Giordano F J Transl Med. 2024; 22(1):375.

PMID: 38643121 PMC: 11032602. DOI: 10.1186/s12967-024-05192-w.


Development and Metabolomic Profiles of (Diptera: Tephritidae) Larvae Exposed to Phytosanitary Irradiation Dose in Hypoxic Environment Using DI-SPME-GC/MS.

Shan C, Li B, Li L, Liu Q, Zou H, Liu T Insects. 2024; 15(3).

PMID: 38535372 PMC: 10971714. DOI: 10.3390/insects15030177.


References
1.
Florio M, Magenta A, Beji S, Lakatta E, Capogrossi M . Aging, MicroRNAs, and Heart Failure. Curr Probl Cardiol. 2019; 45(12):100406. PMC: 10544917. DOI: 10.1016/j.cpcardiol.2018.12.003. View

2.
Zhang X, Wang X, Yuan Z, Radford S, Liu C, Libutti S . Amino acids-Rab1A-mTORC1 signaling controls whole-body glucose homeostasis. Cell Rep. 2021; 34(11):108830. PMC: 8062038. DOI: 10.1016/j.celrep.2021.108830. View

3.
Cardoso R, Graffunder F, Ternes C, Fernandes A, Rocha A, Fernandes G . SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: A systematic review and meta-analysis. EClinicalMedicine. 2021; 36:100933. PMC: 8257984. DOI: 10.1016/j.eclinm.2021.100933. View

4.
Marfella R, DOnofrio N, Trotta M, Sardu C, Scisciola L, Amarelli C . Sodium/glucose cotransporter 2 (SGLT2) inhibitors improve cardiac function by reducing JunD expression in human diabetic hearts. Metabolism. 2021; 127:154936. DOI: 10.1016/j.metabol.2021.154936. View

5.
Davidson M, Nesti C, Palenzuela L, Walker W, Hernandez E, Protas L . Novel cell lines derived from adult human ventricular cardiomyocytes. J Mol Cell Cardiol. 2005; 39(1):133-47. DOI: 10.1016/j.yjmcc.2005.03.003. View